share_log

海宁皮城(002344):Q1扣非净利同比增长16.62% 关注公司经营转型提效进展

Haining Picheng (002344): Q1 deducted non-net profit increased by 16.62% compared with the same period last year. Follow the progress of the company's business transformation and efficiency improvement.

中金公司 ·  Apr 29, 2021 00:00

1Q21's performance is in line with our expectations.

Haining Picheng announced 1Q21 annual results: operating income of 300 million yuan, an increase of 12.35% over the same period last year, and net profit of 97 million yuan, an increase of 46.91% over the same period last year, which is basically in line with our expectations. After deducting non-recurrent profit and loss, the net profit was 70 million yuan, an increase of 16.62% over the same period last year. Non-recurrent profit and loss mainly came from fair value changes, investment income and government subsidies.

Development trend

1. 1Q21's annual revenue increased by 12.35% compared with the same period last year. The company's 1Q21 achieved revenue of 300 million yuan, an increase of 12.35% over the same period last year, and the growth rate decreased by 7.1ppt compared with the previous month. The operating cost was 175 million yuan, an increase of 33.77% over the same period last year, mainly due to the carry-over of property sales costs and the increase in depreciation of new items. The net cash flow from operating activities was 240 million yuan, compared with 9.86 million yuan in the same period last year, mainly due to the increase in cash received from government subsidies and the sale of goods and services over the same period last year.

2. The ability of cost control has been slightly improved during the period. 1Q21's gross profit margin fell 9.32ppt to 41.8% year-on-year, mainly due to the carry-over of the cost of property sales and the increase in depreciation of new items. On the expense side, the company continued to strengthen cost control. During the 1Q21 period, the expense rate decreased by 0.81ppt to 12.9%; the sales expense rate decreased by 1.83ppt to 6.1%; the management and R & D expense rate decreased by 0.59ppt to 6.7%; and the financial expense rate increased by 1.61ppt to 0.1% compared with the same period last year, mainly due to the increase in bank loan interest expenses. Under the comprehensive influence, the 1Q21 net interest rate increased by 7.6ppt to 32.3% year-on-year, mainly due to the decrease in expense rate and the increase in investment income; deducting the non-net interest rate increased by 0.86ppt to 23.3% compared with the same period last year.

3. Follow up to pay attention to the progress of improving efficiency in the transformation of the company's management. 1) consolidate and upgrade the main business, push through the old and bring forth the new: consolidate and upgrade the main leather industry, superimpose the development of the fashion industry, expand peer cooperation and exchanges, promote the docking of the ecosystem upstream and downstream of the industrial chain, and expand new media channels. 2) the second major health cause continues to advance: Yihe Nursing Hospital has been fully transformed and opened, approved by designated medical insurance institutions at the same time, the operation of the rehabilitation hospital has been improved, and the core team, organization and business structure have been optimized. 3) accelerate online and offline integration and open digital intelligence construction: cooperate to establish the country's first fur category Douyin e-commerce live broadcast base, cooperate with Aliyun New Retail to promote Taobao "Cloud Market" project, and cooperate with Kuaishou to establish Haining Leather City clothing industry belt. The follow-up recovery of the main business and the effect of business transformation still need to be tracked continuously.

Profit forecast and valuation

Maintain the profit forecast of 0.16 yuan per share in 2021 and introduce the profit forecast of 0.17 yuan per share in 2022. The current share price corresponds to a price-to-earnings ratio of 25x / 23x in 2022. Maintain the neutral rating and target price of 4.33 yuan, corresponding to 27 times Pmax E in 2021 and 25 times Pamp E in 2022, with 12% room for increase.

Risk

Competition in the industry continues to intensify, online transactions are diverted, and the progress of the big health business is not as expected.

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment